Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Young

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Journal of Experimental Medicine|August 6, 2014
RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast developmentRakesh Verma, Su Su, Donald J McCrann, et al.
Biochemical and Biophysical Research Communications|June 11, 2016
RVX-297- a novel BD2 selective inhibitor of BET bromodomainsOlesya A Kharenko, Emily M Gesner, Reena G Patel, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 12, 2003
Induction of endogenous genes by peroxisome proliferator activated receptor alpha ligands in a human kidney cell line and in vivoPhillip C C Liu, Reid Huber, Mark D Stow, et al.
Data in Brief|August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytesSylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Blood Advances|November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AMLNeil Beeharry, Sean Landrette, Sophia Gayle, et al.
Atherosclerosis|July 14, 2014
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient miceRavi Jahagirdar, Haiyan Zhang, Salman Azhar, et al.
Molecular Pharmacology|October 5, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune DiseaseRavi Jahagirdar, Sarah Attwell, Suzana Marusic, et al.
Gene|June 14, 2002
Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promotersReid M Huber, Kathleen Murphy, Bowman Miao, et al.
Journal of Medicinal Chemistry|August 31, 2018
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a MethionineOlesya A Kharenko, Reena G Patel, S David Brown, et al.
Plos One|January 7, 2014
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonistKevin G McLure, Emily M Gesner, Laura Tsujikawa, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Journal of Experimental Medicine|August 6, 2014
RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast developmentRakesh Verma, Su Su, Donald J McCrann, et al.
Biochemical and Biophysical Research Communications|June 11, 2016
RVX-297- a novel BD2 selective inhibitor of BET bromodomainsOlesya A Kharenko, Emily M Gesner, Reena G Patel, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 12, 2003
Induction of endogenous genes by peroxisome proliferator activated receptor alpha ligands in a human kidney cell line and in vivoPhillip C C Liu, Reid Huber, Mark D Stow, et al.
Data in Brief|August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytesSylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Blood Advances|November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AMLNeil Beeharry, Sean Landrette, Sophia Gayle, et al.
Atherosclerosis|July 14, 2014
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient miceRavi Jahagirdar, Haiyan Zhang, Salman Azhar, et al.
Molecular Pharmacology|October 5, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune DiseaseRavi Jahagirdar, Sarah Attwell, Suzana Marusic, et al.
Gene|June 14, 2002
Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promotersReid M Huber, Kathleen Murphy, Bowman Miao, et al.
Journal of Medicinal Chemistry|August 31, 2018
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a MethionineOlesya A Kharenko, Reena G Patel, S David Brown, et al.
Plos One|January 7, 2014
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonistKevin G McLure, Emily M Gesner, Laura Tsujikawa, et al.
Pageof 3